Navigation Links
Cell Biosciences Acquires Brightwell Technologies
Date:5/12/2011

SANTA CLARA, Calif., May 12, 2011 /PRNewswire/ -- Cell Biosciences, Inc. today announced that it has acquired Brightwell Technologies, Inc. of Ottawa, Ontario for approximately U.S. $9 million in cash.

Brightwell Technologies is the market leader in Micro-Flow Imaging (MFI), an analytical technique used to detect particles and aggregates in protein-based therapeutics. Because of high interest in protein aggregation expressed by the FDA and other regulatory agencies, Brightwell's MFI products have experienced widespread adoption by the world's largest pharmaceutical and biotechnology companies. Brightwell was founded in 2001 and employs approximately 30 people at its headquarters in Ottawa, Ontario. Brightwell's 2011 revenues are expected to be approximately U.S. $5 million.

The acquisition of Brightwell Technologies significantly strengthens Cell Biosciences' position in the high-growth protein therapeutics market. Cell Biosciences entered that market in October 2010, with the acquisition of Convergent Bioscience. Convergent's products for protein characterization are used by virtually every major producer of protein therapeutics. Because Brightwell's MFI products are targeted at the same customer set, this transaction is expected to fuel additional market penetration for both product lines.

Commenting on the transaction, Tim Harkness, President and Chief Executive Officer of Cell Biosciences, said, "Brightwell's MFI platform holds the leading position in an important emerging market, and represents a great strategic fit with existing Cell Biosciences products. This is our fourth acquisition in 18 months and it represents another important step in our plan to build a highly focused and differentiated protein analysis pure-play."

Peter Moore, President of Brightwell Technologies, added, "We are extremely pleased to be joining Cell Biosciences. This transaction creates exciting opportunities for our people, and the cultural fit between
'/>"/>

SOURCE Cell Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
3. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
4. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
5. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
6. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
7. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
8. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
9. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
10. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
11. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
(Date:7/24/2014)... BUFFALO, N.Y. Primary care treatment of overweight and ... and child compared to when only the child is ... Pediatrics and conducted at the University at Buffalo ... in this study were overweight or obese and had ... was overweight or obese, according to body mass index ...
(Date:7/24/2014)... caffeine may worsen the hot flashes and night sweats ... through menopause, new survey data suggests. "While these ... intake may be useful for those postmenopausal women who ... Dr. Stephanie Faubion, director of the Women,s Health Clinic ... caffeine -- a stimulant found in coffee and colas ...
(Date:7/24/2014)... 24, 2014 A new study led by the ... interplay among bacteria, viruses and the immune system during ... their potential to infect others based on ... amounts of virus in their semen despite having low ... different levels of the virus can be found in ...
(Date:7/24/2014)... July 24, 2014 Memantine was initially developed ... marketed in Germany under the brand name Akatinol; it was ... as Ebixa and in the USA to Forest Labs as ... million in 2013. In the US, Forest reported Namenda sales ... expiry in Canada, Australia and the European region has increased ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... contrast to normal cells, which only divide a finite number ... growth arrest or simply die, cancer cells never cease to ... have uncovered an important clue to one of the mechanisms ... April 22, 2011 issue of Molecular Cell , reveal ...
... -- A new poll finds that almost all parents of ... get exercise during each school day. However, one-third said their ... survey findings come at a time when U.S. schools continue ... Obesity is thought to affect one out of every six ...
... Monitoring Committee (DSMC) has determined that patients in a ... a standard chemotherapy regimen for advanced prostate cancer did ... patients on the same chemotherapy regimen who got a ... had advanced, hormone-refractory prostate cancer were given up to ...
... a high school athlete drops dead, the rare but ... For reasons that remain a mystery to scientists, some ... experience an unusual heart arrhythmia. With over-exertion, their hearts ... now, screening for the hard-to-detect syndrome has been prohibitively ...
... the worm is shedding light on a protein associated with ... a highly targeted way to treat them. University ... which is present in many cell types but whose exact ... protein controls key aspects of the movement, or secretion, of ...
... Even people who show a clear treatment ... like insomnia, sadness and decreased concentration, researchers at ... data from the largest study on the treatment ... working overall, missed these symptoms. If patients have ...
Cached Medicine News:Health News:A new ending to an old 'tail' 2Health News:A new ending to an old 'tail' 3Health News:U.S. Parents Want Kids More Active During School Day: Poll 2Health News:Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer 2Health News:Standing up for athletes at risk 2Health News:Worm studies shed light on human cancers 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 3
... The THERMOstar is a high performance temperature ... microplates. Temperature, shaking speed and incubation time ... the status parameters are displayed on the ... above and below the microplates provide uniform ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9 Broth...
An agent used for making solid microbiological media....
Medicine Products: